Evento

Effect of Roscovitine and mifepristone in luminal breast cancer cells

Vottero, Lucía; Lanari, Claudia Lee MalvinaIcon ; Fabris, Victoria TeresaIcon
Tipo del evento: Reunión
Nombre del evento: American Association for Cancer Research Virtual Annual Meeting II
Fecha del evento: 22/06/2020
Institución Organizadora: American Association for Cancer Research;
Título de la revista: Cancer Research
Editorial: American Association for Cancer Research
ISSN: 0008-5472
e-ISSN: 1538-7445
Idioma: Inglés
Clasificación temática:

Resumen

The cyclin dependent kinase (CDK)4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) have been recently approved in combination with endocrine therapy for luminal breast cancer treatment. On the other hand, the use of CDK2 inhibitors, such as Roscovitine, appears as a therapeutic alternative to overcome the acquisition of resistance to Palbociclib. However, there are few clinical trials using CDK2 inhibitors for breast cancer treatment. Most of the reports on the effects of Roscovitine were performed in MCF-7 or MDA-MB-231 cells.
Palabras clave: BREAST CANCER , CDK INHIBITORS , ENDOCRINE THERAPY , PROGESTERONE RECEPTOR , ANTIPROGESTINS
 
Archivos asociados
Tamaño: 119.7Kb
Formato: PDF
Descripción: Acceso al texto del resumen completo desde los enlaces propuestos.
.
Licencia
info:eu-repo/semantics/restrictedAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/264803
URL: https://cancerres.aacrjournals.org/content/80/16_Supplement/5828
DOI: http://dx.doi.org/10.1158/1538-7445.AM2020-5828
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Effect of Roscovitine and mifepristone in luminal breast cancer cells; American Association for Cancer Research Virtual Annual Meeting II; San Diego; Estados Unidos; 2020; 5828-5828
Compartir
Altmétricas